Advanced Cancer Diagnostics Market Size Worth USD 138.81 Billion by 2034 | CAGR: 9.1%

The advanced cancer diagnostics market size is expected to reach USD  138.81 Billion by 2034, according to a new study by Polaris Market Research. The report “Advanced Cancer Diagnostics Market Share, Size, Trends, Industry Analysis Report: By Test, By Indication, By End User, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Advanced cancer diagnostics solutions provide early detection, accurate monitoring, and personalized testing for various cancer types. These solutions cover tumor marker tests, imaging-based diagnostics, molecular testing, genetic testing, and liquid biopsy, supporting hospitals, laboratories, and research institutes with efficient, minimally invasive, and scalable diagnostic services.

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/advanced-cancer-diagnostics-market/request-for-sample

Market growth is driven by rising cancer prevalence, aging populations, and increasing healthcare expenditure. Moreover, AI integration, digitalization, and advanced diagnostic technologies are enhancing test accuracy, operational efficiency, and global competitiveness.

Advanced Cancer Diagnostics Market Report Highlights

• Based on test, tumor marker tests dominated in 2024, driven by widespread adoption in early detection and routine monitoring.
• In terms of indication, lung cancer diagnostics expected fastest growth due to rising incidence and awareness.
• Based on end user, hospital associated labs dominated in 2024, supported by high patient throughput and advanced infrastructure.
• North America dominated in 2024, backed by strong hospital infrastructure and high diagnostic adoption.
• Asia Pacific projected fastest CAGR, fueled by expanding medical infrastructure and government screening programs.
• Key players in the global market include Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific Inc., Hologic, Inc., Qiagen, Bio-Rad Laboratories, Inc., Danaher Corporation, Sysmex Corporation, Becton Dickinson & Co., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., and Myriad Genetics, Inc.

Polaris Market Research has segmented the market report based on test, indication, end user, and region:

By Test Outlook (Revenue, USD Billion, 2020–2034)

• Tumor Marker Tests
• Fine Needle Aspiration Cytology (FNAC) & Biopsy
• Imaging-Based Diagnostics
• Bone Marrow Aspiration & Biopsy
• Immunohistochemistry (IHC) & Molecular Testing
• Genetic Testing for Cancer
• Liquid Biopsy

By Indication Outlook (Revenue, USD Billion, 2020–2034)

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Blood Cancer
• Prostate Cancer
• Ovarian Cancer
• Stomach Cancer
• Liver Cancer
• Other Indications

By End User Outlook (Revenue, USD Billion, 2020–2034)

• Hospital Associated Labs
• Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Other End Users

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America